- Home
- TOST vs JAZZ Comparison
TOST vs JAZZ Comparison
Compare TOST & JAZZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TOST | JAZZ |
|---|---|---|
| Founded | 2012 | 2003 |
| Country | United States | Ireland |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 19.9B | 16.1B |
| IPO Year | 2021 | 2007 |
Fundamental Metrics
Financial Performance| Metric | TOST | JAZZ |
|---|---|---|
| Price | $33.95 | $246.81 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 22 | 14 |
| Target Price | $41.29 | ★ $217.57 |
| AVG Volume (30 Days) | ★ 8.5M | 924.3K |
| Earning Date | 05-07-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 1766.67 | N/A |
| EPS | 0.46 | ★ 7.17 |
| Revenue | ★ $6,153,000,000.00 | $1,618,693,000.00 |
| Revenue This Year | $22.69 | $6.22 |
| Revenue Next Year | $18.03 | $7.68 |
| P/E Ratio | $74.00 | ★ $34.53 |
| Revenue Growth | ★ 24.05 | N/A |
| 52 Week Low | $22.26 | $123.89 |
| 52 Week High | $42.15 | $266.38 |
Technical Indicators
Market Signals| Indicator | TOST | JAZZ |
|---|---|---|
| Relative Strength Index (RSI) | 49.89 | 48.05 |
| Support Level | $33.45 | $237.05 |
| Resistance Level | $34.52 | $265.71 |
| Average True Range (ATR) | 1.17 | 7.82 |
| MACD | -0.46 | -1.03 |
| Stochastic Oscillator | 30.55 | 25.75 |
Price Performance
Historical ComparisonAbout TOST Toast Inc.
Toast Inc is a cloud-based, all-in-one digital technology platform purpose-built for the restaurant community. The company provides a comprehensive platform of software-as-a-service (SaaS) products and financial technology solutions, including integrated payment processing, restaurant-grade hardware, and a broad ecosystem of third-party partners. It serves as a restaurant operating system, connecting front of house and back of house operations across service models such as dine-in, takeout, and delivery. It operates through one reportable segment consisting of its SaaS products, financial technology solutions, integrated payments, hardware, and partner ecosystem.
About JAZZ Jazz Pharmaceuticals plc (Ireland)
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.